tbuckley/cabot-search huggingface dataset:
Abstract 1950: SMURF1 inhibition reduces cancer stem cell-like population in head and neck squamous cell carcinoma
Authors: Ali Khammanivong, Raj Gopalakrishnan, Erin B. Dickerson
Journal: Cancer Research (2014)

Abstract Cancer stem cells (CSCs) possess capabilities for long-term survival (quiescence), self-renewal, and tumor initiation thought to be responsible for drug resistance and treatment failures for many malignancies, including head and neck squamous cell carcinoma (HNSCC). Previously, we showed that the activity of bone morphogenetic protein (BMP), a key regulator of cell differentiation, proliferation, migration, and apoptosis, is inhibited in CSC-like populations enriched from HNSCC cell lines. In contrast, the BMP signaling inhibitor SMAD specific E3 ubiquitin protein ligase 1 (SMURF1) and CD44, a marker of CSCs, were upregulated. Objectives: In this study, we characterized the role of SMURF1 for CSC maintenance and differentiating growth and identified a population of cells regulated by SMURF1. Methods: We generated a stable knockdown of SMURF1 expression in CSC-like populations using a lentivirus delivered shRNA interference construct. Long-term colony formation and Calcein AM dye efflux assays were performed to assess CSC maintenance and differentiating growth. Results: Knockdown of SMURF1 expression by shRNA reduced viability and colony formation of CSC-like cells grown in three-dimensional culture. Furthermore, reduced SMURF1 expression diminished the number of cells capable of dye efflux and decreased CD44 expression (CD44-high) in a select cell population. Conclusion: We interpret our data to suggest that SMURF1 inhibition of BMP signaling potentiates the long-term survival of HNSCC CSCs. Reduced dye efflux and expression of CD44-high cells suggests decreased maintenance of CSC-like populations along with an increased potential for differentiating growth. Targeting SMURF1 may provide a long-term benefit for HNSCC treatment to reduce resistant CSC populations and disease recurrence. Citation Format: Ali Khammanivong, Raj Gopalakrishnan, Erin B. Dickerson. SMURF1 inhibition reduces cancer stem cell-like population in head and neck squamous cell carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1950. doi:10.1158/1538-7445.AM2014-1950
Post-Excisional Biopsy Seroma on FDG-PET Scan in Patients with Breast Cancer Can Conceal Residual Malignancy
Authors: Yu JQ, Kung JW, Dadparvar S, Alavi A, Zhuang HM
Journal: Clinical Nuclear Medicine (2005)

Greater New York and New England Chapters, the Society of Nuclear Medicine 18th Annual Northeast Regional Scientific Session Abstracts October 22–October 24, 2004—Stamford, Connecticut: PDF Only
Adenosine in exercise adaptation.
Authors: R E Simpson, J W Phillis
Journal: British Journal of Sports Medicine (1992)

By influencing the regulation of the mechanisms of angiogenesis, erythropoietin production, blood flow, myocardial glucose uptake, glycogenolysis, systolic blood pressure, respiration, plasma norepinephrine and epinephrine levels, adenosine may exert a significant effect on the body's adaptation response to exercise. However, adenosine's possible influence over the vasodilatory response to exercise in skeletal muscle is controversial and more research is required to resolve this issue. Various popular exercise training methods, such as cyclic training, interval training, and the 'warm down' from training may increase adenosine levels and thereby might enhance the response of adenosine-influenced adaptive mechanisms. Among the several classes of drugs which may enhance extracellular adenosine levels and thereby might augment adenosine-influenced adaptive mechanisms, are the anabolic steroidal and some readily available non-steroidal anti-inflammatory drugs (NSAIDs).
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Authors: Joy N Tsai, Alexander V Uihlein, Hang Lee, Ruchit Kumbhani, Erica Siwila-Sackman, Elizabeth A McKay, Sherri-Ann M Burnett-Bowie, Robert M Neer, Benjamin Z Leder
Journal: The Lancet (2013)
Chimerism of the Transplanted Heart
Authors: Federico Quaini, Konrad Urbanek, Antonio P. Beltrami, Nicoletta Finato, Carlo A. Beltrami, Bernardo Nadal-Ginard, Jan Kajstura, Annarosa Leri, Piero Anversa
Journal: New England Journal of Medicine (2002)

Cases in which a male patient receives a heart from a female donor provide an unusual opportunity to test whether primitive cells translocate from the recipient to the graft and whether cells with the phenotypic characteristics of those of the recipient ultimately reside in the donor heart. The Y chromosome can be used to detect migrated undifferentiated cells expressing stem-cell antigens and to discriminate between primitive cells derived from the recipient and those derived from the donor.
Effects of Ventilation Style on Surfactant Metabolism and Treatment Response in Preterm Lambs
Authors: MACHIKO IKEGAMI, KAZUKO WADA, GEORGE A. EMERSON, CELSO M. REBELLO, RAFAEL E. HERNANDEZ, ALAN H. JOBE
Journal: American Journal of Respiratory and Critical Care Medicine (1998)

We investigated whether the style of ventilation would influence respiratory physiology or surfactant metabolism in surfactant-treated preterm lambs. Preterm lambs were delivered at 131 ± 1 d gestation and treated with an organic solvent extract of sheep surfactant (100 mg/kg). The lambs were randomized to ventilation peiods of 2 h, 5 h, 10 h, or 24 h, and to ventilation with a low rate (15 breaths/min) and high Vt (15 ml/kg), with a high rate (50 breaths/min) and low Vt (8 ml/kg), or with high-frequency oscillatory ventilation (HFOV). Gas exchange and lung volumes were similar across time and for the different ventilation styles. Saturated phosphatidylcholine (SatPC) in alveolar lavage was lower for the HFOV group than for the other ventilation groups at 10 h and 24 h. The rate of loss of surfactant protein B (SP-B) from these preterm animals' lungs was slow and not influenced by ventilation style. The percentages of surfactants in large-aggregate forms were not changed by style of ventilation, and the large-aggregate surfactants had excellent function when tested in surfactant- deficient preterm rabbits. Alveolar lavage protein was low (30 ml/kg), and tissue hyaluronan did not change with time or ventilation style. In preterm lambs ventilated without causing injury, the extreme styles of ventilation examined in the study had minimal effects on lung function, surfactant function, or surfactant metabolism.
Psychoanalysis of Playing
Authors: Mauricio Abadi
Journal: Psychotherapy and Psychosomatics (1967)

Research Articles| February 12 2010 Psychoanalysis of Playing Subject Area: Psychiatry and Psychology Mauricio Abadi Mauricio Abadi Buenos Aires Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1967) 15 (2-4): 85–93. https://doi.org/10.1159/000285881 Article history Published Online: February 12 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Mauricio Abadi; Psychoanalysis of Playing. Psychother Psychosom 31 December 1967; 15 (2-4): 85–93. https://doi.org/10.1159/000285881 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search This content is only available via PDF. 1967Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
More CJD Cases to Come?
Authors: Joan Stephenson
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sexual behavior in Japanese quail as a test end point for endocrine disruption: effects of in ovo exposure to ethinylestradiol and diethylstilbestrol.
Authors: K Halldin, C Berg, I Brandt, B Brunström
Journal: Environmental Health Perspectives (1999)

Chemicals having a capacity to disturb the endocrine system have attracted considerable interest during recent years. There is a shortage of well-characterized in vivo tests with which to study such disturbances in different classes of vertebrates. In the present study, test end points related to reproduction in the Japanese quail were used to examine the estrogenic activity of chemicals. The synthetic estrogens ethinylestradiol (EE(2)) and diethylstilbestrol (DES), used as model compounds, were injected into the yolk of embryonated eggs. After the birds had been raised to sexual maturity, we examined sexual behavior, plasma testosterone concentrations, and testis morphology in adult males. The lowest doses resulting in a significantly depressed male sexual behavior were 6 ng/g egg for EE(2) and 19 ng/g egg for DES. Testis weight asymmetry was increased at 6 ng EE(2)/g egg, but DES had no effect at any treatment level. The area of the androgen-dependent cloacal gland was significantly reduced at 57 ng DES/g egg. No effects on plasma testosterone concentration or body weight following exposure to EE(2) or DES were observed at any dose level. Depressed male sexual behavior was the most sensitive of the end points studied, and we suggest that this ecologically relevant end point be included in avian in vivo testing for neuroendocrine disruptors.
Transplanting Human Tissue: Ethics, Policy, and Practice
Authors: Peter Furness
Journal: BMJ (2004)

Human tissue should not be bought or sold for profit. Agreed? But it's OK to pay “legitimate expenses,” “handling charges,” “processing costs,” and so on. So the boundaries are blurred. How far can this be stretched?

The answer, perhaps inevitably, comes from the United States. The US situation is the sole subject of this book. Furthermore, the “tissue” under consideration is largely restricted to musculoskeletal tissues and skin; whole organs are specifically excluded. Publication was …
Somatostatinoma Syndrome
Authors: G. J. Krejs, L. Orci, J. M. Conlon, M. Ravazzola, G. R. Davis, Philip Raskin, S. M. Collins, D. M. McCarthy, D. Baetens, A. Rubenstein, T. A. Aldor, Roger H Unger
Journal: New England Journal of Medicine (1979)

Diabetes mellitus, steatorrhea, cholelithiasis and a tumor distorting the duodenum prompted a work-up for somatostatinoma in a 52-year-old man. The responses of pancreatic B-cells but not of A-cells to nutrient stimuli were inhibited, and growth-hormone release was suppressed, suggesting somatostatin resistance in some target tissues. Plasma somatostatin-like immunoreactivity ranged from 9000 to 13,000 pg per milliliter (normal: 88+/-8, mean +/- S.E.M.) and was distributed in four molecular forms, including free somatostatin. The primary tumor contained 5 microgram of somatostatin-like immunoreactivity per milligram of wet tissue, distributed in three of the molecular forms noted in plasma. Plasma calcitonin was also elevated (4650 pg per milliliter; normal: less than 120). Immunocytochemical studies showed that cells of the primary tumor contained somatostatin and calcitonin but no other peptide hormones. Only somatostatin was present in the metastases. Somatostatin was localized electron microscopically in all secretory granules, irrespective of size and shape, whereas calcitonin was present only within a single subpopulation of small granules in the same cells.
Clofazimine should be used in all cases of leprosy, says Indian research council
Authors: S. Bhaumik
Journal: BMJ (2013)

Clofazimine should be added to the regimen of drugs used to treat paucibacillary leprosy, the Indian Council of Medical Research has recommended.1

Clofazimine is a lipophilic riminophenazine antibiotic with antibacterial and anti-inflammatory properties. The latest recommendation from the Indian Council of Medical Research is based on a review it conducted on published data that showed that clofazimine “can be safely used . . . along with dapsone and rifampicin for the 6 month multidrug therapy (MDT) being used in the treatment of paucibacillary leprosy.” 

India achieved …
Carinal granuloma after endotracheal intubation.
Authors: N Abeyewickreme, P M Simpson
Journal: BMJ (1977)

Absence of uterine neoplasia in patients on bromocriptineBromocriptine is a dopamine agonist which is used to suppress prolactin secretion postpartum and in men and women with gonadal dysfunction; to suppress growth hormone secretion in acromegaly; and to treat Parkinsonism.Initial toxicological studies in rats showed no adverse effects over 53 weeks except for the presence of endometrial hyperplasia with squamous metaplasia and cystic ovarian follicles.'The preliminary results of a 100-week study in rats have now shown, however, that the endometrial changes have progressed in some animals to malignant tumours.2For this reason we have screened gynaecologic- ally all of our available patients who have received bromocriptine. Patients and methodsOf the 108 women, 21 were acromegalic; 49 had hyperprolactinaemic gonadal dysfunction (29 pituitary tumours); 19 had normoprolactinaemic infertility or galactorrhoea, or both; 18 had polycystic ovarian disease (16 with hyperprolactinaemia); and one had Cushing's disease.Ten of these patients were pregnant and 10 had had hysterectomies; these had been for benign conditions except in one patient who had an endometrial carcinoma removed before starting bromocriptine.Eleven of the remaining 88 were postmenopausal, and all 88 patients were assessed gynaecologically.Bromo- criptine treatment had lasted for four to six years in six patients; two to four years in 24; one to two years in 37; and less than one year in 21.The dose of bromocriptine varied from 1-25 mg to 60 mg daily; 64 patients received 5 to 10 mg daily.Twenty women had stopped treatment for between six months and three years.As an outpatient each patient underwent a gynaecological examination, cervical smear, and endometrial suction curettage using a Vabra aspirator without sedation or anaesthesia.The endometrial aspirate and cervical smears were stained for cytological examination by the Papanicolaou method, and when sufficient material was available endo- metrium was fixed, embedded in paraffin wax, and sectioned for histological examination using haematoxylin and eosin staining.Cervical and endometrial assessment was not possible in the 10 pregnant patients and the 10 who had had hysterectomies.No gross gynaecological abnormalities were found in the remaining 88 patients, except uterine fibroids in one.No cytological or histological evidence of endometrial neoplasia, metaplasia, or hyperplasia or cervical abnormalities were found in any of the tissues studied (see table ).Results of gynaecological assessment in 88 women* treated with bromocriptine No ('",) of women with Evidence of neoplasia, enough tissue for hyperplasia, hyperplasia assessment or m etplasia Pre-Postmenopausal menopausal Cervical cytology 77 (100) 9 (82) 0 Endometrial cytology 74 (96) 5 (45) 0 Endometrial histology 61 (79) 1 ( 9) 0 *These women were left after 10 pregnant women and 10 women who had had hysterectomies had been excluded.
Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear
Authors: Athol U Wells
Journal: Thorax (2012)

In treatment trials in idiopathic pulmonary fibrosis (IPF), there is an unmet need for an accurate primary end point. A European-wide consensus exists that mortality is not a practicable primary end point for the demonstration of beneficial treatment effects in IPF.1 Serial, 6-min-walk test data are confounded by factors other than progression of interstitial lung disease. Alone among other candidate variables, trends in forced vital capacity (FVC) have consistently predicted mortality in IPF2–11 and can, thus, be viewed as the best marker of chronic disease progression. FVC trends are now the preferred primary end point in IPF treatment trials, although not a proven surrogate for mortality.12

In pharmaceutical studies, FVC change is analysed as a continuous variable, or by designating thresholds for change as ‘significant’ and quantifying time to FVC decline. Analyses of continuous change are more sensitive. However, FVC change thresholds have important theoretical advantages. Progression in IPF occurs in a stepwise fashion in some patients, and is not necessarily captured by evaluation of FVC change as a continuous variable. The designation of ‘significant’ FVC decline allows patients with ‘treatment failure’ to exit a trial with no need to continue on a demonstrably ineffective blinded therapy. In addition, time to decline in FVC can be amalgamated with mortality in evaluations of ‘progression-free survival’.

The absence of consensus on the optimum FVC threshold for change in IPF prompted Richeldi et al 13 to compare the prognostic value of candidate thresholds. The prevailing confusion on this question cannot be overstated. In 2000, significant FVC change in IPF was designated as a 10% change from baseline, but it was unclear whether this recommendation referred to ‘relative change’ (a 10% change from baseline values—eg, from 60% to 54% of predicted), or ‘absolute change’ (a 10% reduction in percentage predicted values—eg, …
A comparative study on body composition of male and female national level sub-junior volleyball players
Authors: Sanjib Mridha
Journal: British Journal of Sports Medicine (2010)

Introduction Body composition is an important aspect of health for every individual. It influences sport performance to a great extent. There is almost no difference in body composition of males and females in the early childhood but as they advance in age that differences becomes insidious. The purpose of this study was to compare the body composition of male and female national level sub-junior volleyball players. Methods Male (N = 67) and female (N = 42) sub-junior that is, under 17 years (U-17), volleyball players from six states of India were the subjects of this study. Body composition of the two groups were understood by height, weight, body mass index (BMI), percentage body fat (BF%), fat mass (FM), lean body mass (LBM) and waist-to-hip ratio (WHR). Data of each variable of male and female groups were compared (independent t test) and the level of significance was set at p &lt;0.05 level. Results Significant difference between the two groups was observed in height, weight, BF%, FM, LBM and WHR. Male group was superior in height, weight, LBM and WHR, and female group was superior in BF% and FM than the other group. No difference was observed in BMI of the two groups. Thus the study was concluded as, except BMI, there was difference in body composition of male and female national level sub-junior volleyball players. Female group tend to have greater adiposity than male group and the male group was superior in other body composition variables.
Sex Differences in Clinical Predictors of Suicidal Acts After Major Depression: A Prospective Study
Authors: Maria A. Oquendo, Mary E. Bongiovi-Garcia, Hanga Galfalvy, Pablo H. Goldberg, Michael F. Grunebaum, Ainsley K. Burke, J. John Mann
Journal: American Journal of Psychiatry (2007)

Objective: Whether sex differences exist in clinical risk factors associated with suicidal behavior is unknown. The authors postulated that among men with a major depressive episode, aggression, hostility, and history of substance misuse increase risk for future suicidal behavior, while depressive symptoms, childhood history of abuse, fewer reasons for living, and borderline personality disorder do so in depressed women. Method: Patients with DSM-III-R major depression or bipolar disorder seeking treatment for a major depressive episode (N=314) were followed for 2 years. Putative predictors were tested with Cox proportional hazards regression analysis. Results: During follow-up, 16.6% of the patients attempted or committed suicide. Family history of suicidal acts, past drug use, cigarette smoking, borderline personality disorder, and early parental separation each more than tripled the risk of future suicidal acts in men. For women, the risk for future suicidal acts was sixfold greater for prior suicide attempters; each past attempt increased future risk threefold. Suicidal ideation, lethality of past attempts, hostility, subjective depressive symptoms, fewer reasons for living, comorbid borderline personality disorder, and cigarette smoking also increased the risk of future suicidal acts for women. Conclusions: These findings suggest that the importance of risk factors for suicidal acts differs in depressed men and women. This knowledge may improve suicide risk evaluation and guide future research on suicide assessment and prevention.